Etrasimod Arginine Patent Expiration
Etrasimod Arginine is Used for treating ulcerative colitis by administering Estrasimod Arginine. It was first introduced by Pfizer Inc
Etrasimod Arginine Patents
Given below is the list of patents protecting Etrasimod Arginine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Velsipity | US10301262 | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders | Jun 21, 2036 | Pfizer |
| Velsipity | US10676435 | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound 1) for use in SIPI receptor-associated disorders | Jun 21, 2036 | Pfizer |
| Velsipity | US11091435 | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in S1P1 receptor-associated disorders | Jun 21, 2036 | Pfizer |
| Velsipity | US11884626 | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders | Jun 21, 2036 | Pfizer |
| Velsipity | US11007175 | Methods of treating conditions related to the S1P1 receptor | Jan 06, 2036 | Pfizer |
| Velsipity | US12156866 | Methods of treating conditions related to the S1P1 receptor | Jan 06, 2036 | Pfizer |
| Velsipity | US12377071 | Methods Of Treating Conditions Related To The S1P1 Receptor | Jan 06, 2036 | Pfizer |
| Velsipity | US8580841 | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders | Mar 05, 2030 | Pfizer |
| Velsipity | US9126932 | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders | Jul 22, 2029 | Pfizer |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Etrasimod Arginine's patents.
Latest Legal Activities on Etrasimod Arginine's Patents
Given below is the list recent legal activities going on the following patents of Etrasimod Arginine.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 20 Jun, 2025 | US8580841 |
| transaction for FDA Determination of Regulatory Review Period | 02 May, 2025 | US8580841 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Jan, 2025 | US11091435 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Jan, 2025 | US8580841 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 15 Jan, 2025 | US11091435 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Oct, 2024 | US11007175 |
| Second letter to regulating agency to determine regulatory review period | 16 May, 2024 | US8580841 |
| Letter from FDA or Dept of Agriculture re PTE application | 08 May, 2024 | US8580841 |
| Email Notification Critical
| 30 Jan, 2024 | US11884626 |
| Mail Patent eGrant Notification | 30 Jan, 2024 | US11884626 |
Etrasimod Arginine's Family Patents
